GRAIL (NASDAQ:GRAL) Hits New 12-Month High - Here's Why

Key Points

• GRAIL shares surged to a new 12-month high of $126.81 after FDA advisers backed Galleri’s safety and narrowly supported its effectiveness, moving the cancer-detection test closer to final FDA review.
• Additional PATHFINDER 2 clinical data and a higher Baird price target reinforced investor optimism, though the narrow efficacy vote leaves significant regulatory uncertainty and Goldman Sachs maintains a “hold” rating.
• The stock’s rally has outpaced analyst expectations: its consensus rating is “Hold” with an average price target of $75.10, while GRAIL remains unprofitable despite quarterly revenue and adjusted earnings beating estimates.

GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) shares hit a new 52-week high during mid-day trading on Friday. The stock traded as high as $126.81 and last traded at $125.21, with a volume of 3442777 shares changing hands. The stock had previously closed at $108.52.

More GRAIL News

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: FDA advisers backed Galleri’s safety and narrowly supported the evidence for its effectiveness. The vote represents important regulatory progress for GRAIL and its primary commercial product. FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy
• Positive Sentiment: The recommendation moves Galleri closer to final FDA review. Approval could significantly expand GRAIL’s addressable market, strengthen confidence in its technology and support additional adoption of the prescription test. Grail's Multi-Cancer Blood Test Gets FDA Committee Vote
• Positive Sentiment: GRAIL also reported PATHFINDER 2 study findings, providing additional clinical data as investors evaluate Galleri’s effectiveness and commercial potential ahead of the FDA decision. GRAIL Reports PATHFINDER 2 Study Findings
• Positive Sentiment: Robert W. Baird raised its price target to $118 from $96 and maintained an “outperform” rating, reflecting greater optimism about Galleri’s regulatory outlook.
• Neutral Sentiment: Trading was temporarily halted ahead of the FDA meeting because of pending news, underscoring the event’s significance and contributing to unusually high volatility. Grail Trading Halted Ahead of FDA AdCom Meeting
• Neutral Sentiment: A report lists short interest at zero shares, implying no measurable short-selling pressure; however, the figure may reflect a reporting anomaly and should be interpreted cautiously.
• Negative Sentiment: The committee’s support for efficacy was narrow, leaving meaningful regulatory uncertainty before the FDA issues its final decision. Goldman Sachs has a “hold” rating, signaling caution after the rally. GRAIL Gets a Hold from Goldman Sachs
• Negative Sentiment: CEO Joshua Ofman and CFO Aaron Freidin sold shares under pre-arranged Rule 10b5-1 plans. The transactions were scheduled and leave both executives with substantial holdings, but may still weigh modestly on sentiment.

Analysts Set New Price Targets

GRAL has been the topic of a number of recent research reports. Robert W. Baird lifted their price target on shares of GRAIL from $96.00 to $118.00 and gave the stock an "outperform" rating in a research note on Tuesday. The Goldman Sachs Group started coverage on shares of GRAIL in a research note on Friday, June 5th. They issued a "neutral" rating and a $60.00 price objective for the company. TD Cowen reiterated a "buy" rating on shares of GRAIL in a research report on Thursday. Royal Bank Of Canada assumed coverage on shares of GRAIL in a research report on Thursday, September 17th. They set a "sector perform" rating and a $84.00 target price on the stock. Finally, Wall Street Zen raised shares of GRAIL from a "sell" rating to a "hold" rating in a research note on Sunday, September 13th. Five equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $75.10.

GRAIL Price Performance

The stock has a market capitalization of $5.59 billion, a price-to-earnings ratio of -12.84 and a beta of 3.25. The firm has a 50 day simple moving average of $77.33 and a 200-day simple moving average of $65.25.

GRAIL (NASDAQ:GRAL - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, topping the consensus estimate of ($2.66) by $0.10. The business had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. On average, sell-side analysts forecast that GRAIL, Inc. will post -10.41 earnings per share for the current fiscal year.

Insider Transactions at GRAIL

In other GRAIL news, CEO Joshua Ofman sold 61,452 shares of the business's stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $97.74, for a total value of $6,006,318.48. Following the transaction, the chief executive officer directly owned 362,271 shares in the company, valued at $35,408,367.54. The trade was a 14.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Freidin sold 7,900 shares of the firm's stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $85.01, for a total transaction of $671,579.00. Following the sale, the chief financial officer directly owned 253,083 shares of the company's stock, valued at approximately $21,514,585.83. The trade was a 3.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 78,452 shares of company stock worth $7,485,691. Company insiders own 1.83% of the company's stock.

Institutional Investors Weigh In On GRAIL

A number of large investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd acquired a new stake in GRAIL during the 4th quarter valued at $28,000. Fifth Third Bancorp boosted its stake in GRAIL by 15,733.3% in the first quarter. Fifth Third Bancorp now owns 475 shares of the company's stock worth $25,000 after purchasing an additional 472 shares in the last quarter. Allworth Financial LP bought a new stake in shares of GRAIL during the second quarter worth $35,000. Geneos Wealth Management Inc. grew its holdings in shares of GRAIL by 160.0% during the first quarter. Geneos Wealth Management Inc. now owns 585 shares of the company's stock worth $30,000 after purchasing an additional 360 shares during the last quarter. Finally, Osbon Capital Management LLC acquired a new stake in shares of GRAIL in the fourth quarter valued at $51,000.

About GRAIL

GRAIL, Inc is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company's primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.

GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.